Key points from article :
Muvon Therapeutics has announced promising results from its first-in-human (FIH) Phase I clinical trial for a regenerative therapy targeting stress urinary incontinence (SUI) in women. The trial results, now published in the International Urogynecology Journal, demonstrate the safety and feasibility of using autologous muscle precursor cells to treat this common and debilitating condition.
Deana Mohr, CEO of Muvon Therapeutics, highlighted the importance of this milestone, emphasizing the successful peer-reviewed validation of the approach. John F. Coelho, leading Medical Affairs, noted the therapy was well-tolerated by patients and generated significant interest at the European Association of Urology Annual Congress in Milan.
The trial employed comprehensive, internationally recognized outcome measures, including patient-reported questionnaires, a one-hour pad test, urodynamics, and MRI assessments, to evaluate changes in muscle thickness and identify any potential issues. The positive findings pave the way for Muvon’s exploratory Phase II program, which is proceeding on schedule. These results mark a critical step forward in developing innovative treatments for SUI, offering hope to millions affected by the condition.
